Final 5-year report of BIONYX comparing the thin-composite wire-strut zotarolimus-eluting stent versus ultrathin-strut sirolimus-eluting stent.
coronary artery disease
drug‐eluting stent
long‐term follow‐up
percutaneous coronary intervention
randomized controlled trial
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
07 May 2024
07 May 2024
Historique:
received:
11
04
2024
accepted:
20
04
2024
medline:
7
5
2024
pubmed:
7
5
2024
entrez:
7
5
2024
Statut:
aheadofprint
Résumé
The BIONYX randomized trial is the first study to evaluate the Resolute Onyx durable polymer-coated zotarolimus-eluting stent (ZES) in all-comers. Furthermore, it is the first trial to assess safety and efficacy of this stent versus the Orsiro biodegradable-polymer sirolimus-eluting stent (SES) in all-comers, paying particular attention to patients with diabetes. It has previously shown promising results until 3 years of follow-up. We aimed to assess long-term clinical outcome after percutaneous coronary intervention (PCI) with Onyx ZES versus Orsiro SES at 5-year follow-up. The main composite endpoint was target vessel failure (TVF): cardiac death, target vessel myocardial infarction, or target vessel revascularization. Time to primary and secondary endpoints was assessed using Kaplan-Meier methods, applying the log-rank test for between-group comparison. Follow-up was available in 2414/2488 (97.0%) patients. After 5 years, TVF showed no significant difference between Onyx ZES and Orsiro SES (12.7% vs. 13.7%, hazard ratio [HR] 0.94, 95% confidence interval [CI] [0.75-1.17], p The final 5-year analysis of the randomized BIONYX trial showed favorable and similar long-term outcomes of safety and efficacy for Onyx ZES and Orsiro SES in both all-comers and patients with diabetes.
Sections du résumé
BACKGROUND
BACKGROUND
The BIONYX randomized trial is the first study to evaluate the Resolute Onyx durable polymer-coated zotarolimus-eluting stent (ZES) in all-comers. Furthermore, it is the first trial to assess safety and efficacy of this stent versus the Orsiro biodegradable-polymer sirolimus-eluting stent (SES) in all-comers, paying particular attention to patients with diabetes. It has previously shown promising results until 3 years of follow-up.
AIMS
OBJECTIVE
We aimed to assess long-term clinical outcome after percutaneous coronary intervention (PCI) with Onyx ZES versus Orsiro SES at 5-year follow-up.
METHODS
METHODS
The main composite endpoint was target vessel failure (TVF): cardiac death, target vessel myocardial infarction, or target vessel revascularization. Time to primary and secondary endpoints was assessed using Kaplan-Meier methods, applying the log-rank test for between-group comparison.
RESULTS
RESULTS
Follow-up was available in 2414/2488 (97.0%) patients. After 5 years, TVF showed no significant difference between Onyx ZES and Orsiro SES (12.7% vs. 13.7%, hazard ratio [HR] 0.94, 95% confidence interval [CI] [0.75-1.17], p
CONCLUSIONS
CONCLUSIONS
The final 5-year analysis of the randomized BIONYX trial showed favorable and similar long-term outcomes of safety and efficacy for Onyx ZES and Orsiro SES in both all-comers and patients with diabetes.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Medtronic
Organisme : Biotronik
Informations de copyright
© 2024 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals LLC.
Références
von Birgelen C, Zocca P, Buiten RA, et al. Thin composite wire strut, durable polymer‐coated (Resolute Onyx) versus ultrathin cobalt‐chromium strut, bioresorbable polymer‐coated (Orsiro) drug‐eluting stents in allcomers with coronary artery disease (BIONYX): an international, single‐blind, randomised non‐inferiority trial. Lancet. 2018;392:1235‐1245.
Price MJ, Shlofmitz RA, Spriggs DJ, et al. Safety and efficacy of the next generation Resolute Onyx zotarolimus‐eluting stent: primary outcome of the RESOLUTE ONYX core trial. Catheter Cardiovasc Interv. 2018;92:253‐259.
Buiten RA, Zocca P, von Birgelen C. Thin, very thin, or ultrathin‐strut biodegradable or durable polymer‐coated drug‐eluting stents. Curr Opin Cardiol. 2020;35:705‐711.
Kedhi E, Généreux P, Palmerini T, et al. Impact of coronary lesion complexity on drug‐eluting stent outcomes in patients with and without diabetes mellitus. J Am Coll Cardiol. 2014;63:2111‐2118.
Koskinas KC, Siontis GC, Piccolo R, et al. Impact of diabetic dtatus on outcomes after revascularization with drug‐eluting stents in relation to coronary artery disease complexity: patient‐level pooled analysis of 6081 patients. Circ Cardiovasc Interv. 2016;9:e003255.
Heath JM, Sun Y, Yuan K, et al. Activation of AKT by O‐linked N‐acetylglucosamine induces vascular calcification in diabetes mellitus. Circ Res. 2014;114:1094‐1102.
Schunkert H, Harrell L, Palacios IF. Implications of small reference vessel diameter in patients undergoing percutaneous coronary revascularization. J Am Coll Cardiol. 1999;34:40‐48.
Windecker S, Haude M, Neumann FJ, et al. Comparison of a novel biodegradable polymer sirolimus‐eluting stent with a durable polymer everolimus‐eluting stent: results of the randomized BIOFLOW‐II trial. Circ Cardiovasc Interv. 2015;8:e001441.
Kim SH, Kang SH, Lee JM, et al. Three‐year clinical outcome of biodegradable hybrid polymer Orsiro sirolimus‐eluting stent and the durable biocompatible polymer resolute integrity zotarolimus‐eluting stent: a randomized controlled trial. Catheter Cardiovasc Interv. 2020;96:1399‐1406.
Kandzari DE, Koolen JJ, Doros G, et al. Ultrathin bioresorbable polymer sirolimus‐eluting stents versus durable polymer everolimus‐eluting stents: BIOFLOW V final 5‐year outcomes. JACC Cardiovasc Interv. 2022;15:1852‐1860.
Buiten RA, Ploumen EH, Zocca P, et al. Thin composite‐wire‐strut zotarolimus‐eluting stents versus ultrathin‐strut sirolimus‐eluting stents in BIONYX at 2 years. JACC Cardiovasc Interv. 2020;13:1100‐1109.
Ploumen EH, Buiten RA, Zocca P, et al. First report of 3‐year clinical outcome after treatment with novel Resolute Onyx stents in the randomized BIONYX trial. Circ J. 2021;85:1983‐1990.
Hansen KN, Jensen LO, Maeng M, et al. Five‐year clinical outcome of the biodegradable polymer ultrathin strut sirolimus‐eluting stent compared to the biodegradable polymer biolimus‐eluting stent in patients treated with percutaneous coronary intervention: from the SORT OUT VII trial. Circ Cardiovasc Interv. 2023;16:e012332.
Pilgrim T, Piccolo R, Heg D, et al. Ultrathin‐strut, biodegradable‐polymer, sirolimus‐eluting stents versus thin‐strut, durable‐polymer, everolimus‐eluting stents for percutaneous coronary revascularisation: 5‐year outcomes of the BIOSCIENCE randomised trial. Lancet. 2018;392:737‐746.
Ploumen EH, Pinxterhuis TH, Buiten RA, et al. Final 5‐year report of the randomized BIO‐RESORT trial comparing 3 contemporary drug‐eluting stents in all‐comers. J Am Heart Assoc. 2022;11:e026041.
Vranckx P, Cutlip D, Mehran R, et al. Myocardial infarction adjudication in contemporary all‐comer stent trials: balancing sensitivity and specificity. EuroIntervention. 2010;5:871‐874.
Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344‐2351.
Windecker S, Latib A, Kedhi E, et al. Polymer‐based versus polymer‐free stents in high bleeding risk patients. JACC Cardiovasc Interv. 2022;15:1153‐1163.
Kedhi E, Latib A, Abizaid A, et al. Rationale and design of the Onyx ONE global randomized trial: a randomized controlled trial of high‐bleeding risk patients after stent placement with 1month of dual antiplatelet therapy. Am Heart J. 2019;214:134‐141.
Kandzari DE, Koolen JJ, Doros G, et al. Ultrathin bioresorbable‐polymer sirolimus‐eluting stents versus thin durable‐polymer everolimus‐eluting stents for coronary revascularization. JACC Cardiovasc Interv. 2020;13:1343‐1353.
Bavishi C, Chugh Y, Kimura T, et al. Biodegradable polymer drug‐eluting stent vs. contemporary durable polymer drug‐eluting stents in patients with diabetes: a meta‐analysis of randomized controlled trials. Eur Heart J Qual Care Clin Outcomes. 2020;6:81‐88.
Ploumen EH, Buiten RA, Kok MM, et al. Treating diabetic all‐comers with contemporary drug‐eluting stents: prespecified comparisons from the BIO‐RESORT and the BIONYX randomized trials. Int J Cardiol. 2021;325:37‐44.
Romaguera R, Salinas P, Gomez‐Lara J, et al. Amphilimus‐ vs. zotarolimus‐eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial. Eur Heart J. 2022;43:1320‐1330.
Woods T. Dysregulation of the mammalian target of Rapamycin and p27Kip1 promotes intimal hyperplasia in diabetes mellitus. Pharmaceuticals. 2013;6:716‐727.